Overview:
As the treatment landscape for hepatocellular carcinoma (HCC) continues to evolve, multidisciplinary, coordinated therapeutic intervention remains the cornerstone of care for these patients. Expert insights into treatment selection and collaborative decision-making are critical to informing and optimizing patient outcomes in resectable and unresectable disease.
This hybrid Liver Cancer Tumor Board® symposium will bring together renowned experts in the management of HCC. In this educational program, these experts will share clinical insights and advances in the management of HCC with novel neoadjuvant, adjuvant, and perioperative immunotherapy-based therapeutic strategies.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Assess the efficacy and safety of current and emerging adjuvant and neoadjuvant treatment strategies for early-stage resectable hepatocellular carcinoma (HCC) and appropriate patient selection
- Analyze the efficacy and safety of current and emerging therapies and combinations for management of patients with intermediate stage and advanced/metastatic HCC
- Develop personalized care plans for patients with early-, intermediate-stage as well as advanced/metastatic HCC by integrating clinical trial evidence, expert guidelines, tumor characteristics, patient co-morbidities, and goals of therapy
- Devise proactive plans for monitoring and mitigating treatment-related adverse events associated with current and emerging therapies for patients with HCC
Richard S. Finn, MD
Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Santa Monica, CA
Anthony B. El-Khoueiry, MD
Associate Director for Clinical Research
USC Norris
Associate Professor of Clinical Medicine
Keck School of Medicine of USC
Los Angeles, CA
Pierre Gholam, MD
Professor of medicine , Department of Medicine
Case Western Reserve University School of Medicine
Medical director, Liver Center of Excellence
University Hospitals
Cleveland, OH
Lipika Goyal, MD
Associate Professor of Medicine
Stanford Medicine
Stanford, CA
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.